Among patients who carry apolipoprotein E allele ε4 (ApoEε4), an allele which increases the risk of developing AD, Bapineuzumab was associated with reduced cerebrospinal fluid (CSF) phospho-tau concentrations and a decreased rate of accumulation of Aβ in the brain [83]. The gene discussed is MAPT; the disease is Alzheimer disease.